Accreditation/
Credit Designation
Accreditation/Credit Designation:
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity will be made available for 1.0 AMA PRA Category 1.0 Credits.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Acknowledgement of Commercial Support:
This CME program is supported by an educational grant from Gilead Sciences, Inc.
Oncology Best Practices™: Strategic Algorithms for Challenging Cases in Relapsed/Refractory Multiple Myeloma
.png)
Oncology Best Practices™: Strategic Algorithms for Challenging Cases in Relapsed/Refractory Multiple Myeloma
Overview
Oncology Best Practice™ is a nationwide series of live, regional activities held in locations across the US that are deemed to have the highest educational need. This educational activity will focus on the selection and sequencing of therapy for relapsed/refractory (R/R) multiple myeloma (MM). New data will be presented, treatment algorithms to improve care will be explored, and challenging cases and supportive measures for patients who have been exposed to multiple rounds of therapy will be discussed. We look forward to your joining us to learn how to bring the latest innovative cancer treatment to your patients.
Benefits of Attending
- Enjoy an evening of direct interaction with experts in R/R MM
- Learn how the experts and your peers manage challenging cases of heavily pretreated R/R MM
- Ask experts about best practices in supportive care for patients with R/R MM who have been exposed to multiple rounds of therapy
Target Audience
This activity is directed toward medical oncologists and hematologist/oncologists who treat or manage patients with multiple myeloma. Other oncology healthcare professionals, including nurses and pharmacists who manage patients with multiple myeloma, are also invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Explain the impact of risk stratification and treatment resistance on decision-making among patients with multiple myeloma in early relapse
- Examine efficacy and safety results from clinical trials conducted among patients with relapsed/refractory multiple myeloma in later lines of therapy
- Apply mitigation strategies to reduce and treat adverse events associated with newer agents for relapsed/refractory multiple myeloma
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at [email protected]
Start date: November 30, 2021
Register
You must be logged in to PER to register for this meeting
Or Register for PER now
*Required Fields
Login Information
Registration Information
In case of onsite emergency:
Professional Information
Specialties*
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.
